Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
Abstract Background Denosumab is a major treatment option for patients with postmenopausal osteoporosis; however, the evidence for its use is lacking. Therefore, in this 24-month retrospective study, we aimed to evaluate the effects of switching from minodronate (MIN) to denosumab in these patients....
Main Authors: | Masaki Kobayashi, Kenjiro Sawada, Akihiko Yoshimura, Misa Yamamoto, Aasa Shimizu, Kotaro Shimura, Naoko Komura, Mayuko Miyamoto, Kyoso Ishida, Tadashi Kimura |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | BMC Women's Health |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12905-020-00913-x |
Similar Items
-
Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene
by: Toda A, et al.
Published: (2017-11-01) -
The effects of minodronate and activated vitamin D on bone mineral density and muscle mass in postmenopausal women with osteoporosis
by: Kazuki Fujimoto, et al.
Published: (2018-04-01) -
Minodronate for the treatment of osteoporosis
by: Ohishi T, et al.
Published: (2018-04-01) -
A review of minodronic acid hydrate for the treatment of osteoporosis
by: Tanishima S, et al.
Published: (2013-02-01) -
Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study
by: Mizue Tanaka, et al.
Published: (2017-03-01)